Gensana M, Altisent C, Aznar J A, Casaña P, Hernández F, Jorquera J I, Magallón M, Massot M, Puig L
Research and Development Area, Instituto Grifols, SA, Barcelona, Spain.
Haemophilia. 2001 Jul;7(4):369-74. doi: 10.1046/j.1365-2516.2001.00526.x.
In order to determine the difference in reactivity of factor (F) VIII inhibitors against the FVIII/von Willebrand factor (vWF) complex and against vWF-deficient FVIII, we investigated a panel of 10 antibodies to FVIII from multitransfused individuals with severe haemophilia A and other pathologies. Immunoblotting of purified FVIII and purified thrombin-cleaved FVIII revealed that in all cases inhibitor epitopes could be localized in the heavy chain (A2 subunit) while in four cases they were also present in the light chain. One of the FVIII inhibitors remained unclassified. The effect on FVIII:C of purified IgG from inhibitor plasmas was tested against a high purity FVIII/vWF concentrate and a monoclonally purified FVIII concentrate with only trace contents of vWF, by two different functional assays. Our results suggest that for those inhibitors showing A2 plus light chain (LC) reactivity, the IgG concentration required to inhibit 50% of FVIII activity in vitro is higher for the FVIII/vWF complex than for the vWF-deficient FVIII. We conclude that there might be a protective role of vWF (at least in vitro) against FVIII inhibitors with A2 and LC subunit specificity.
为了确定因子(F)VIII抑制剂对FVIII/血管性血友病因子(vWF)复合物和对缺乏vWF的FVIII的反应性差异,我们研究了一组来自患有严重甲型血友病和其他病症的多次输血个体的10种抗FVIII抗体。对纯化的FVIII和纯化的经凝血酶切割的FVIII进行免疫印迹分析显示,在所有情况下,抑制剂表位均可定位在重链(A2亚基)中,而在4种情况下,它们也存在于轻链中。其中一种FVIII抑制剂仍未分类。通过两种不同的功能测定法,测试了来自抑制剂血浆的纯化IgG对高纯度FVIII/vWF浓缩物和仅含微量vWF的单克隆纯化FVIII浓缩物的FVIII:C的影响。我们的结果表明,对于那些显示A2加轻链(LC)反应性的抑制剂,体外抑制50%FVIII活性所需的IgG浓度,对于FVIII/vWF复合物而言高于缺乏vWF的FVIII。我们得出结论,vWF(至少在体外)可能对具有A2和LC亚基特异性的FVIII抑制剂具有保护作用。